Sagility Limited has made a regulatory disclosure regarding an acquisition by its wholly owned subsidiary, Sagility (US) Holdings Inc. The Board of Directors approved the transaction at their meeting held on October 21, 2026.

Acquisition Details

Sagility (US) Holdings Inc. signed a definitive agreement on October 21, 2026, to acquire Chirok Health LLC, a US-based healthcare services company. The acquisition involves 100% ownership of Chirok Health LLC.

Target Company Information

Chirok Health LLC operates in the healthcare services sector, specifically Healthcare Revenue Cycle Management (RCM), including Clinical Documentation Integrity (CDI) and medical coding services. The company was incorporated in 2019 and is headquartered in Tennessee, United States.

Financial performance of Chirok Health LLC:

  • CY2023 turnover: USD 12.7 million
  • CY2024 turnover: USD 8.2 million
  • CY2025 turnover: USD 9.0 million

The company utilizes its proprietary CHEMP workflow platform to deliver services including audit and quality assurance services.

Transaction Structure

The aggregate purchase consideration is up to USD 32.35 million, structured as:

  • Upfront payment of USD 20.0 million at closing, subject to customary closing adjustments
  • Contingent consideration of up to USD 12.35 million, payable subject to achievement of specified performance milestones

The consideration will be paid entirely in cash. The transaction does not constitute a related party transaction, and no promoter/promoter group/group companies have any interest in the entity being acquired.

Strategic Rationale

The acquisition is intended to strengthen Sagility's capabilities in the provider segment by adding specialized Clinical Documentation Integrity (CDI), medical coding and revenue optimization capabilities, complementing Sagility's existing healthcare services portfolio.

Regulatory Approvals and Timeline

No governmental or regulatory approvals are required for the acquisition. The indicative time-period for completion of the acquisition is October 21, 2026.

Compliance Framework

The disclosure is made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.